Angiotensin-converting enzyme 2 receptors, chronic liver diseases, common medications, and clinical outcomes in coronavirus disease 2019 patients

doi:10.5501/wjv.v10.i3.86

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 3

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (12274)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series.

Item

Count

PDF

495

WORD

229

HTML

5918

Figures (1-1)

1407

Sum=8049

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

416

Download

1242

Sum=1658

Publishing Process of This Article

Item

Count

Browse

751

Download

1805

Sum=2556

May 25, 2021 (publication date) through Feb 16, 2026

Times Cited of This Article

Times Cited (7)

Journal Information of This Article

Publication Name

World Journal of Virology

ISSN

2220-3249

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Minireviews

World J Virol. May 25, 2021; 10(3): 86-96
Published online May 25, 2021. doi: 10.5501/wjv.v10.i3.86

Angiotensin-converting enzyme 2 receptors, chronic liver diseases, common medications, and clinical outcomes in coronavirus disease 2019 patients

Wattana Leowattana

Wattana Leowattana, Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, Bangkok 10400, Thailand

Author contributions: Leowattana W collected the data and wrote the paper.

Conflict-of-interest statement: The author declares no conflict of interest for this article.

Corresponding author: Wattana Leowattana, BSc, MD, MSc, PhD, Associate Professor, Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, 420/6 Rajavithi Road, Rachatawee, Bangkok 10400, Thailand. wattana.leo@mahidol.ac.th

Received: January 28, 2021
Peer-review started: January 28, 2021
First decision: February 24, 2021
Revised: March 10, 2021
Accepted: April 26, 2021
Article in press: April 26, 2021
Published online: May 25, 2021
Processing time: 109 Days and 20.5 Hours

Core Tip

Core Tip: With more than 100 million confirmed cases worldwide, hepatobiliary injury has been reported in many coronavirus disease 2019 (COVID-19) patients. The association between COVID-19 and hepatobiliary injury refers to any hepatobiliary damage during disease progression and treatment in COVID-19 patients with or without chronic liver diseases or common medications. Angiotensin-converting enzyme 2 receptor may be a significant factor in hepatobiliary derangement due to its high expression in cholangiocytes, and it is also an entry point of severe acute respiratory syndrome coronaviruses 2. Moreover, drug-induced liver injury and cytokine storm may be an added risk in severe clinical outcomes. Close monitoring of liver function in COVID-19 patients is mandatory.